STOCK TITAN

Hims & Hers (HIMS) Chief Legal Officer sells 4,812 shares under 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Hims & Hers Health, Inc. Chief Legal Officer Soleil Boughton executed an open-market sale of 4,812 shares of Class A common stock at $24.69 per share. After this transaction, she directly holds 308,831 shares. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025, indicating it was scheduled in advance rather than timed opportunistically.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Boughton Soleil

(Last)(First)(Middle)
2269 CHESTNUT STREET, #523

(Street)
SAN FRANCISCO CALIFORNIA 94123

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock03/17/2026S(1)4,812D$24.69308,831D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on November 18, 2025 by the Reporting Person.
Remarks:
/s/ Kimberly Mather, Attorney-in-Fact for Soleil Boughton03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Hims & Hers (HIMS) Chief Legal Officer report in this Form 4?

Hims & Hers Chief Legal Officer Soleil Boughton reported an open-market sale of 4,812 Class A common shares at $24.69 each. Following the sale, she directly owns 308,831 shares, according to the filing’s post-transaction ownership disclosure.

How large is Soleil Boughton’s Hims & Hers (HIMS) share sale compared to her remaining holdings?

Soleil Boughton sold 4,812 Hims & Hers shares while retaining 308,831 shares after the transaction. This indicates she continues to hold a significantly larger position than the number of shares sold in this particular trade.

Was the Hims & Hers (HIMS) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025. Such plans pre-schedule trades, reducing the likelihood that the timing reflects short-term views on the stock.

What type of transaction did the Hims & Hers (HIMS) Form 4 disclose?

The Form 4 discloses an open-market sale of Class A common stock, coded “S” for sale. It is a non-derivative transaction, meaning it involved common shares directly rather than options, warrants, or other derivative securities.

How many Hims & Hers (HIMS) shares does the insider hold after the reported sale?

After selling 4,812 Class A common shares, Soleil Boughton directly holds 308,831 shares. This post-transaction ownership figure, disclosed in the filing, shows her remaining equity stake in Hims & Hers following the reported sale.
Hims & Hers Health Inc

NYSE:HIMS

View HIMS Stock Overview

HIMS Rankings

HIMS Latest News

HIMS Latest SEC Filings

HIMS Stock Data

5.67B
205.37M
Drug Manufacturers - Specialty & Generic
Services-offices & Clinics of Doctors of Medicine
Link
United States
SAN FRANCISCO